Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Biological Effects of Radiation02:59

Biological Effects of Radiation

All radioactive nuclides emit high-energy particles or electromagnetic waves. When this radiation encounters living cells, it can cause heating, break chemical bonds, or ionize molecules. The most serious biological damage results when these radioactive emissions fragment or ionize molecules. For example, α and β particles emitted from nuclear decay reactions possess much higher energies than ordinary chemical bond energies. When these particles strike and penetrate matter, they produce ions...
Radiation: Applications01:17

Radiation: Applications

The average temperature of Earth is the subject of much current discussion. Earth is in radiative contact with both the Sun and dark space; it receives almost all its energy from the radiation of the Sun and reflects some of it into outer space. Dark space is very cold, about 3 K, so Earth radiates energy into it. For instance, heat transfer occurs from soil and grasses, the rate of which can be so rapid that frost can occur on clear summer evenings, even in warm latitudes.
The average...
Types of Radioactivity03:23

Types of Radioactivity

The most common types of radioactivity are α decay, β decay, γ decay, neutron emission, and electron capture.
Alpha (α) decay is the emission of an α particle from the nucleus. For example, polonium-210 undergoes α decay:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dosimetry Results from the Phase 1b/3 ACTION-1 Trial of [<sup>225</sup>Ac]Ac-DOTATATE (RYZ101) in Patients with Somatostatin Receptor-Expressing, Well-Differentiated GEP-NETs.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Erratum to Xiao Y, Benedict S, Cui Y, Glide-Hurst C, Graves S, Jia X, KryF S, Li H, Lin L, Matuszak M, Newpower M, Paganetti H, Qi XS, Roncali E, Rong Y, Sgouros G, Simone 2nd CB, Sunderland JJ, Taylor PA, Tchelebi L, Weldon M, Zou JW, Wuthrick EJ, Machtay M, Le QT, Buchsbaum JC. Embracing the future of clinical trials in radiation therapy: an NRG oncology CIRO technology retreat whitepaper on pioneering technologies and AI-driven solutions. Int J of Radiat Oncol Biol Phys 2025:122;443-457.

International journal of radiation oncology, biology, physics·2026
Same author

Combination Radiopharmaceutical Therapy and Radiotherapy for Thyroid Cancer: Dosimetry-Driven Precision Medicine.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025
Same author

Enhanced activity localization and microscale dosimetry in alpha-emitter radiopharmaceutical therapy using integrated autoradiography and histological imaging.

Scientific reports·2025
Same author

Respiratory Signal Estimation for Free-Hand 2D Ultrasound Image via Heterogeneous Alignment and Conditional Generative Learning.

IEEE transactions on bio-medical engineering·2025
Same author

Three-dimensional cell culture models in respiratory virus research: technological advances and current applications.

Journal of materials chemistry. B·2025
Same journal

[<sup>68</sup>Ga]Ga-DOTA-TOC Synthesis by a Cassette Developer System with [<sup>68</sup>Ga]GaCl<sub>3</sub> from Cyclotron using Liquid Target: An Italian Experience.

Current radiopharmaceuticals·2025
Same journal

Evaluating the Effectiveness of Geant4 Software in Measuring the Damage Caused by Ti48 Ion Radiation on Nerve Cells, in Comparison to the Biophysical Model and Empirical Data.

Current radiopharmaceuticals·2025
Same journal

Synergistic Potential of GLP-1 Receptor Agonists and Radiotherapy in Breast Cancer Treatment: A New Therapeutic Avenue (TROD-GROG 006).

Current radiopharmaceuticals·2025
Same journal

Real-world Data on Intermediate-risk Differentiated Thyroid Cancer Biochemical Response to 3700 or 5550 MBq of [<sup>131</sup>I]Sodium Iodide.

Current radiopharmaceuticals·2025
Same journal

RNA Binding Proteins are Pivotal Regulators of Cancer Radioresistance and Potential Targets for Preventing Tumor Recurrence.

Current radiopharmaceuticals·2025
Same journal

Nuclear Nanomedicines: Utilization of Radiolabelling Strategies, Drug Formulation, Delivery, and Regulatory Aspects for Disease Management.

Current radiopharmaceuticals·2025
See all related articles

Related Experiment Video

Updated: May 26, 2026

Irradiator Commissioning and Dosimetry for Assessment of LQ &alpha; and &beta; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

Modelling and dosimetry for alpha-particle therapy.

George Sgouros1, Robert F Hobbs, Hong Song

  • 1Russel H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, School of Medicine, Baltimore, MD 21231, USA. gsgouros@jhmi.edu

Current Radiopharmaceuticals
|December 29, 2011
PubMed
Summary
This summary is machine-generated.

Alpha-particle radiopharmaceuticals offer potent cancer therapy. Accurate micro-scale dosimetry requires pharmacokinetic data, necessitating pre-clinical studies and modeling for human translation.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Related Experiment Videos

Last Updated: May 26, 2026

Irradiator Commissioning and Dosimetry for Assessment of LQ &alpha; and &beta; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

Area of Science:

  • Nuclear medicine
  • Radiation oncology
  • Pharmacokinetics

Background:

  • Alpha-particle emitting radionuclides show promise for targeted cancer therapy due to their high potency and short range.
  • Understanding the biological effects of alpha-particle radiopharmaceuticals necessitates dosimetry at the micro or multi-cellular scale.
  • Non-uniform irradiation at the micro-scale challenges the predictive power of single absorbed dose values.

Purpose of the Study:

  • To review the requirements for micro-scale dosimetry in alpha-particle radiopharmaceutical therapy.
  • To discuss the need for pre-clinical pharmacokinetic data for accurate dosimetry.
  • To examine pharmacokinetic modeling for translating animal data to human applications.

Main Methods:

  • Review of current challenges in micro-scale dosimetry for alpha-particle therapy.
  • Discussion of pharmacokinetic data acquisition in pre-clinical models.
  • Exploration of pharmacokinetic modeling strategies for macro- to micro-scale extrapolation.

Main Results:

  • Direct measurement of human pharmacokinetic input for micro-scale dosimetry is currently not feasible.
  • Pre-clinical studies are essential for obtaining pharmacokinetic data required for dosimetry calculations.
  • Pharmacokinetic models are crucial for bridging animal and human data, enabling micro-scale kinetic extrapolation.

Conclusions:

  • Accurate micro-scale dosimetry is critical for predicting the biological effects of alpha-particle radiopharmaceuticals.
  • Pre-clinical pharmacokinetic data and robust modeling are indispensable for advancing human alpha-particle therapy.
  • Further research into pharmacokinetic modeling is needed to effectively translate pre-clinical findings to clinical applications.